A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2004
11/18/2004	WO2004087740A3 Preserved and stable compositions containing peptide copper complexes and methods related thereto
11/18/2004	WO2004087052A3 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
11/18/2004	WO2004082625A3 Self-emulsifying compositions, methods of use and preparation
11/18/2004	WO2004078778A3 PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
11/18/2004	WO2004078097A8 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
11/18/2004	WO2004072116A3 ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β
11/18/2004	WO2004069193A9 Methods and compositions for inhibiting cholesterol uptake
11/18/2004	WO2004060403A3 Aprotinin and anglos as carriers across the blood-brain barrier
11/18/2004	WO2004002528A9 Compositions and methods for therapeutic treatment
11/18/2004	WO2003090697B1 Chimeric hybrid analgesics
11/18/2004	WO2003087021A8 Nanoparticle delivery systems and methods of use thereof
11/18/2004	US20040230225 Method and device for electrochemical formation of therapeutic species in vivo
11/18/2004	US20040229945 use in inhibiting angiogenesis in a mammal
11/18/2004	US20040229939 sublingual delivery of tetrahydrocannabinol and suitable for tableting, comprising tetrahydrocannabinol, ethanol, a buffer, an antioxidant, a water-soluble excipient, a detergent, a sweetener, and a glidant, to treat or to ameliorate emesis, anorexia, or chronic or AIDS-related wasting syndrome
11/18/2004	US20040229912 Polymeric delivery formulations of leuprolide with improved efficacy
11/18/2004	US20040229908 Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
11/18/2004	US20040229842 Use of lipid conjugates in the treatment of diseases
11/18/2004	US20040229835 Immunostimulatory nucleic acid molecules
11/18/2004	US20040229831 Compositions and methods for non-parenteral delivery of oligonucleotides
11/18/2004	US20040229821 Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
11/18/2004	US20040229793 Compositions and methods for less immunogenic protein formulations
11/18/2004	US20040229775 Bactericide drug
11/18/2004	US20040229333 Electroprocessed fibrin-based matrices and tissues
11/18/2004	US20040229277 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040229265 Amino-modified polysaccharides and methods of generating and using same
11/18/2004	US20040229212 Recombinant human mannan-binding lectin
11/18/2004	US20040228959 Water soluble hemicellulose derived from soybean cotyledon mixed with perfume and colorant; foods, beverages, cosmetics; storage stability
11/18/2004	US20040228932 Excipient made by mechanically separating fiber rich fraction of Trigonella foenum-graceum seeds from embryos; binders, disintegrants, fillers, dispersants, thickeners; time-release agents; drug delivery
11/18/2004	US20040228923 Pulmonary delivery in treating disorders of the central nervous system
11/18/2004	US20040228922 A crosslinked thermosensitive cellulose gel on a medical device and loaded with a solute is positioned within the body and heated to body temperature to release the solute upon gel shrinkage
11/18/2004	US20040228921 Compositions and methods for delivery of therapeutic agents
11/18/2004	US20040228916 Spray coating insoluble drug particles dissolved in a plasticizer with a solvent-free, powdered enteric coating agent; improved bioavailability and solubility; pollution control
11/18/2004	US20040228914 Formulation
11/18/2004	US20040228913 complexed with the active agent; matrices, gels, hydrogels, films, emulsions or microparticles; personal care products, cosmetics
11/18/2004	US20040228903 Soft drink replacer
11/18/2004	US20040228902 polysiloxane prepolymers with pendant pharmaceutically active leaving groups that are released when hydrolyzed or cured in situ
11/18/2004	US20040228886 such as very low density hollow polymeric microspheres and temperature-sensitive expandable thermoplastic microspheres; gel beads; self-supporting; bulk density; storage stability
11/18/2004	US20040228880 Vaccine composition comprising iron phosphate as vaccine adjuvant
11/18/2004	US20040228879 Streptococcus pneumoniae polysaccharide is conjugated to protein or peptide, and RSV antigen with adjuvant which is stimmulator of (cytotoxic T) lymphocytes
11/18/2004	US20040228865 Prevention and treatment of amyloidogenic disease
11/18/2004	US20040228836 cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC)
11/18/2004	US20040228832 Therapeutic azo-compounds for drug delivery
11/18/2004	US20040228831 polymeric drug conjugates composed of biologically active agents attached to regular repeating linear co-polymers or branched co-polymers by means of an enzymatically cleavable linker; may be used to modify drug solubility, drug bioavailability, drug residence time, drug absorption characteristics
11/18/2004	US20040228830 Multiparticulate compositions of milnacipran for oral administration
11/18/2004	US20040228807 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
11/18/2004	US20040228806 For use in therapy of chronic obstructive pulmonary disease and asthma; an inhalette capsule contains a mixture of coarser and fine excipient particles
11/18/2004	US20040228798 A conjugated drug contains virus-like particle is joined to the antigen by a biotin molecule; bioassay; inhibiting HIV infection, viral infection
11/18/2004	US20040228794 Therapeutic agent carrier compositions
11/18/2004	DE4124409B4 Pharmazeutische Zubereitungen Pharmaceutical preparations
11/18/2004	CA2525191A1 Prodrugs cleavable by cd26
11/18/2004	CA2524924A1 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer
11/18/2004	CA2524891A1 Ultraviolet-shielding type patch
11/18/2004	CA2524615A1 Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
11/18/2004	CA2524580A1 Surfactant mixtures for improving the deposition of active substances and for reducing the skin irritant action
11/18/2004	CA2524286A1 Nasal administration of the lh-rh analog leuprolide
11/18/2004	CA2522345A1 Glycopegylation methods and proteins/peptides produced by the methods
11/18/2004	CA2521928A1 Freeze-dried preparation containing methylcobalamin and process for producing the same
11/18/2004	CA2517338A1 Hiv prodrugs cleavable by cd26
11/18/2004	CA2516820A1 Nanocylinder-modified surfaces
11/17/2004	WO2004107200A1 System and method for controlling user interface properties with data
11/17/2004	EP1477541A1 Pressure sensitive adhesive and patch employing the same
11/17/2004	EP1477496A1 Peg-conjugated pth or peg-conjugated pth derivate
11/17/2004	EP1477189A1 Process for production of pressure-sensitive adhesive moldings comprising crosslinked polymers as the main component
11/17/2004	EP1477187A1 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
11/17/2004	EP1477163A1 New film coating
11/17/2004	EP1477162A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/17/2004	EP1477161A1 Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof
11/17/2004	EP1476574A2 RNA INTERFERENCE MEDIATED INHIBITION OF TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476492A1 Carbohydrate-modified polymers, compositions and uses related thereto
11/17/2004	EP1476489A1 Hydrolytically degradable alkylene oxide based polymers
11/17/2004	EP1476473A1 Novel natural cyclodextrin complexes
11/17/2004	EP1476470A1 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
11/17/2004	EP1476458A2 Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina)
11/17/2004	EP1476457A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SiNA)
11/17/2004	EP1476454A1 Binding epitopes for helicobacter pylori and use thereof
11/17/2004	EP1476199A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
11/17/2004	EP1476198A2 Use of buckysome or carbon nanotube for drug delivery
11/17/2004	EP1476197A2 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
11/17/2004	EP1476196A1 Oral solid solution formulation of a poorly water-soluble active substance
11/17/2004	EP1476195A2 Enhancement of the action of central and peripheral nervous system agents
11/17/2004	EP1476193A1 A weight management system for obese animals
11/17/2004	EP1476191A2 Oral administration of interferon-tau
11/17/2004	EP1476183A1 An immunological adjuvant
11/17/2004	EP1476182A1 Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
11/17/2004	EP1476181A2 Polyalkylene polymer compounds and uses thereof
11/17/2004	EP1476178A2 Formulation strategies in stabilizing peptides in organic solvents and in dried states
11/17/2004	EP1476176A2 Transport peptides and uses therefor
11/17/2004	EP1476171A2 Transportation of nucleic acid substances
11/17/2004	EP1476168A2 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
11/17/2004	EP1476152A2 Use of melatonin analogues for induction of general anesthesia
11/17/2004	EP1476140A1 Taste-masked film-type or wafer-type medicinal preparation
11/17/2004	EP1476139A1 Controlled release dosage forms
11/17/2004	EP1476138A2 Modified release formulations of at least one form of tramadol
11/17/2004	EP1476136A1 Pharmaceutical composition comprising n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation
11/17/2004	EP1476135A1 Ophthalmic formulation with gum system
11/17/2004	EP1476130A1 Preparations containing diol
11/17/2004	EP1476127A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity
11/17/2004	EP1476121A1 Topical ivermectin composition
11/17/2004	EP1476032A1 Water dispersible coenzyme q10 dry powders
11/17/2004	EP1476019A1 Aqueous antiseptic based on bispyridiniumalkanes

1 ... 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 ... 1712